0
0
1/20/23 at 7:00pm
Organization
Targetedonc.com
42 words
0
Comments
Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.
You are the first to view
https://www.targetedonc.com/view/results-from-the-phase-3-nrg-rtog-1112-study-of-sorafenib-in-hcc
Create an account
or login to join the discussion